The GLO1 C332 (Ala111) allele confers autism vulnerability: Family-based genetic association and functional correlates

Journal of Psychiatric Research

Volumn 59, Issue , 2014, Pages 108-116

  Gabriele, Stefano ^a,b   Lombardi, Federica ^a,b   Sacco, Roberto ^a,b   Napolioni, Valerio ^a,b   Altieri, Laura ^a,b,f   Tirindelli, Maria Cristina ^a   Gregorj, Chiara ^a   Bravaccio, Carmela ^c   Rousseau, Francis ^d   Persico, Antonio M ^a,b,e  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Parc Scientifique de Luminy   (France)

^e Mafalda Luce Center for Pervasive Developmental Disorders   (Italy)

^f CHASE FARM HOSPITAL   (United Kingdom)

Author keywords

Advanced glycation end products; Autism; Autism spectrum disorder; Glyoxalase; Methylglyoxal; Pervasive developmental disorders

Indexed keywords

ADVANCED GLYCATION END PRODUCT; LACTOYLGLUTATHIONE LYASE; MESSENGER RNA; ALANINE; GLO1 PROTEIN, HUMAN; SEROTONIN;

ADOLESCENT; ADULT; ALLELE; ARTICLE; ASPERGER SYNDROME; AUTISM; AUTOPSY; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SEQUENCE; ENDOPHENOTYPE; ENZYME ACTIVITY; EXON; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; INTRON; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; BRAIN; FAMILY HEALTH; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; STATISTICS; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; ALANINE; BRAIN; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; FAMILY HEALTH; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LACTOYLGLUTATHIONE LYASE; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 84908311619     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.07.021     Document Type: Article

References (69)

1. Abordo E.A., Minhas H.S., Thornalley P.J. Accumulation of a-oxoaldehydes during oxidative stress: a role in cytotoxicity. Biochem Pharmacol 1999, 58:641-648.
2. Alikhani Z., Alikhani M., Boyd C.M., Nagao K., Trackman P.C., Graves D.T. Advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways. JBiol Chem 2005, 280:12087-12095.
3. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
4. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2013, American Psychiatric Publishing, Arlington, VA. 5th ed.
5. Anney R., Klei L., Pinto D., Almeida J., Bacchelli E., Baird G., et al. Individual common variants exert weak effects on the risk for autism spectrum disorders. Hum Mol Genet 2012, 21:4781-4792.
6. Arai M., Yuzawa H., Nohara I., Ohnishi T., Obata N., Iwayama Y., et al. Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch Gen Psychiatry 2010, 67:589-597.
7. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
8. Barua M., Jenkins E.C., Chen W., Kuizon S., Pullarkat R.K., Junaid M.A. Glyoxalase I polymorphism rs2736654 causing the Ala111Glu substitution modulates enzyme activity-implications for autism. Autism Res 2011, 4:262-270.
9. Ben-Ari Y., Khalilov I., Kahle K.T., Cherubini E. The GABA excitatory/inhibitory shift in brain maturation and neurological disorders. Neuroscientist 2012, 18:467-486.
10. Birkenmeier G., Stegemann C., Hoffmann R., Günther R., Huse K., Birkemeyer C. Posttranslational modification of human glyoxalase 1 indicates redox-dependent regulation. PLoS One 2010, 5:e10399.
11. Boso M., Emanuele E., Minoretti P., Arra M., Politi P., Ucelli di Nemi S., et al. Alterations of circulating endogenous secretory RAGE and S100A9 levels indicating dysfunction of the AGE-RAGE axis in autism. Neurosci Lett 2006, 410:169-173.
12. Campbell D.B., D'Oronzio R., Garbett K., Ebert P.J., Mirnics K., Levitt P., et al. Disruption of cerebral cortex MET signaling in autism spectrum disorder. Ann Neurol 2007, 62:243-250.
13. Centers for Disease Control and Prevention (CDC), Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ 2014, 63:1-21.
14. Chen F., Wollmer M.A., Hoerndli F., Münch G., Kuhla B., Rogaev E.I., et al. Role for glyoxalase I in Alzheimer's disease. Proc Natl Acad Sci USA 2004, 101:7687-7692.
15. Distler M.G., Palmer A.A. Role of Glyoxalase 1 (Glo1) and methylglyoxal (MG) in behavior: recent advances and mechanistic insights. Front Genet 2012, 3:250.
16. Distler M.G., Plant L.D., Sokoloff G., Hawk A.J., Aneas I., Wuenschell G.E., et al. Glyoxalase 1 increases anxiety by reducing GABAA receptor agonist methylglyoxal. JClin Invest 2012, 122:2306-2315.
17. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003, 25:115-121.
18. Fleming T.H., Humpert P.M., Nawroth P.P., Bierhaus A. Reactive metabolites and AGE/RAGE-mediated cellular dysfunction affect the aging process-a minireview. Gerontology 2011, 57:435-443.
19. Fujimoto M., Uchida S., Watanuki T., Wakabayashi Y., Otsuki K., Matsubara T., et al. Reduced expression of glyoxalase-1 mRNA in mood disorder patients. Neurosci Lett 2008, 438:196-199.
20. Garbett K.A., Ebert P.J., Mitchell A., Lintas C., Manzi B., Mirnics K., et al. Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol Dis 2008, 30:303-311.
21. Gardener H., Spiegelman D., Buka S.L. Perinatal and neonatal risk factors for autism: a comprehensive meta-analysis. Pediatrics 2011, 128:344-355.
22. Hambsch B., Chen B.G., Brenndörfer J., Meyer M., Avrabos C., Maccarrone G., et al. Methylglyoxal-mediated anxiolysis involves increased protein modification and elevated expression of glyoxalase 1 in the brain. JNeurochem 2010, 113:1240-1251.
23. Hemptinne F., Rondas D., Toepoel M., Vancompernolle K. Phosphorylation on Thr-106 and NO-modification of glyoxalase I suppress the TNF-induced transcriptional activity of NF-kB. Mol Cell Biochem 2009, 325:169-178.
24. Heo Y., Zhang Y., Gao D., Miller V.M., Lawrence D.A. Aberrant immune responses in a mouse with behavioral disorders. PLoS One 2011, 6:e20912.
25. Horvath S., Xu X., Lake S.L., Silverman E.K., Weiss S.T., Laird N.M. Family-based tests for associating haplotypes with general phenotype data: application to asthma genetics. Genet Epidemiol 2004, 26:61-69.
26. Junaid M.A., Kowal D., Barua M., Pullarkat P.S., Sklower Brooks S., Pullarkat R.K. Proteomic studies identified a single nucleotide polymorphism in glyoxalase I as autism susceptibility factor. Am J Med Genet A 2004, 131:11-17.
27. Kageyama R., Pastan I. Molecular cloning and characterization of a human DNA binding factor that represses transcription. Cell 1989, 59:815-825.
28. Kern J.K., Jones A.M. Evidence of toxicity, oxidative stress, and neuronal insult in autism. JToxicol Environ Health B Crit Rev 2006, 9:485-499.
29. Kim N.S., Sekine S., Kiuchi N., Kato S. cDNA cloning and characterization of human glyoxalase I isoforms from HT-1080 cells. JBiochem 1995, 117:359-361.
30. Klei L., Sanders S.J., Murtha M.T., Hus V., Lowe J.K., Willsey A.J., et al. Common genetic variants, acting additively, are a major source of risk for autism. Mol Autism 2012, 3:9.
31. Kohane I.S., McMurry A., Weber G., MacFadden D., Rappaport L., Kunkel L., et al. The co-morbidity burden of children and young adults with autism spectrum disorders. PLoS One 2012, 7:e33224.
32. Kuhla B., Boeck K., Lüth H.J., Schmidt A., Weigle B., Schmitz M., et al. Age-dependent changes of glyoxalase I expression in human brain. Neurobiol Aging 2006, 27:815-822.
33. Ledig M., Doffoel M., Ziessel M., Kopp P., Charrault A., Tongio M.M., et al. Frequencies of glyoxalase I phenotypes as biological markers in chronic alcoholism. Alcohol 1986, 3:11-14.
34. Leinekugel X., Khalilov I., McLean H., Caillard O., Gaiarsa J.L., Ben-Ari Y., et al. GABA is the principal fast-acting excitatory transmitter in the neonatal brain. Adv Neurol 1999, 79:189-201.
35. Lintas C., Persico A.M. Autistic phenotypes and genetic testing: state-of-the-art for the clinical geneticist. JMed Genet 2009, 46:1-8.
36. Lintas C., Sacco R., Garbett K., Mirnics K., Militerni R., Bravaccio C., et al. Involvement of the PRKCB1 gene in autistic disorder: significant genetic association and reduced neocortical gene expression. Mol Psychiatry 2009, 46:1-8.
37. Lyall K., Pauls D.L., Santangelo S.L., Spiegelman D., Ascherio A. Maternal early life factors associated with hormone levels and the risk of having a child with an autism spectrum disorder in the nurses health study II. JAutism Dev Disord 2011, 41:618-627.
38. Mailankot M., Padmanabha S., Pasupuleti N., Major D., Howell S., Nagaraj R.H. Glyoxalase I activity and immunoreactivity in the aging human lens. Biogerontology 2009, 10:711-720.
39. McLellan A.C., Thornalley P.J. Glyoxalase activity in human red blood cells fractioned by age. Mech Ageing Dev 1989, 48:63-71.
40. Mericq V., Piccardo C., Cai W., Chen X., Zhu L., Striker G.E., et al. Maternally transmitted and food-derived glycotoxins. Diabetes Care 2010, 33:2232-2237.
41. Mitsumoto A., Kim K.R., Oshima G., Kunimoto M., Okawa K., Iwamatsu A., et al. Nitric oxide inactivates glyoxalase I in cooperation with glutathione. JBiochem 2000, 128:647-654.
42. Muratore C.R., Hodgson N.W., Trivedi M.S., Abdolmaleky H.M., Persico A.M., Lintas C., et al. Age-dependent decrease and alternative splicing of methionine synthase mRNA in human cerebral cortex and an accelerated decrease in autism. PLoS One 2013, 8:e56927.
43. Myakishev M.V., Khripin Y., Hu S., Hamer D.H. High-throughput SNP genotyping by allele-specific PCR with universal Energy-Transfer-Labeled primers. Genome Res 2001, 11:163-169.
44. Neale B.M., Kou Y., Liu L., Ma'ayan A., Samocha K.E., Sabo A., et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 2012, 485:242-245.
45. O'Connell J.R., Weeks D.E. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet 1998, 63:259-266.
46. O'Roak B.J., Deriziotis P., Lee C., Vives L., Schwartz J.J., Girirajan S., et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet 2011, 43:585-589.
47. Palmieri L., Papaleo V., Porcelli V., Scarcia P., Gaita L., Sacco R., et al. Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1. Mol Psychiatry 2010, 15:38-52.
48. Palmieri L., Persico A.M. Mitochondrial dysfunction in autism spectrum disorders: cause or effect?. Biochim Biophys Acta 2010, 1797:1130-1137.
49. Persico A.M., Napolioni V. Autism genetics. Behav Brain Res 2013, 251:95-112.
50. Persico A.M., Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci 2006, 29:349-358.
51. Politi P., Minoretti P., Falcone C., Martinelli V., Emanuele E. Association analysis of the functional Ala111Glu polymorphism of the glyoxalase I gene in panic disorder. Neurosci Lett 2006, 396:163-166.
52. Ranganathan S., Ciaccio P.J., Walsh E.S., Tew K.D. Genomic sequence of human glyoxalase-I: analysis of promoter activity and its regulation. Gene 1999, 240:149-155.
53. Rehnström K., Ylisaukko-Oja T., Vanhala R., von Wendt L., Peltonen L., Hovatta I. No association between common variants in glyoxalase 1 and autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:124-127.
54. Sacco R., Lenti C., Saccani M., Curatolo P., Manzi B., Bravaccio C., et al. Cluster analysis of autistic patients based on principal pathogenetic components. Autism Res 2012, 5:137-147.
55. Sacco R., Curatolo P., Manzi B., Militerni R., Bravaccio C., Frolli A., et al. Principal pathogenetic components and biological endophenotypes in autism spectrum disorders. Autism Res 2010, 3:237-252.
56. Sacco R., Papaleo V., Hager J., Rousseau F., Moessner R., Militerni R., et al. Case-control and family-based association studies of candidate genes in autistic disorder and its endophenotypes: TPH2 and GLO1. BMC Med Genet 2007, 8:11.
57. Sacco R., Militerni R., Frolli A., Bravaccio C., Gritti A., Elia M., et al. Clinical, morphological, and biochemical correlates of head circumference in autism. Biol Psychiatry 2007, 62:1038-1047.
58. Shaikh S.B., Uy B., Perera A., Nicholson L.F. AGEs-RAGE mediated up-regulation of connexin43 in activated human microglial CHME-5 cells. Neurochem Int 2012, 60:640-651.
59. Sharma-Luthra R., Kale R.K. Age related changes in the activity of the glyoxalase system. Mech Ageing Dev 1994, 73:39-45.
60. Sick E., Brehin S., André P., Coupin G., Landry Y., Takeda K., et al. Advanced glycation end products (AGEs) activate mast cells. Br J Pharmacol 2010, 161:442-455.
61. Smith S.E., Li J., Garbett K., Mirnics K., Patterson P.H. Maternal immune activation alters fetal brain development through interleukin-6. JNeurosci 2007, 27:10695-10702.
62. Theoharides T.C., Angelidou A., Alysandratos K.D., Zhang B., Asadi S., Francis K., et al. Mast cell activation and autism. Biochim Biophys Acta 2012, 1822:34-41.
63. Thornalley P.J. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems-role in ageing and disease. Drug Metabol Drug Interact 2008, 23:125-150.
64. Van Herreweghe F., Mao J., Chaplen F.W., Grooten J., Gevaert K., Vandekerckhove J., et al. Tumor necrosis factor-induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE. Proc Natl Acad Sci USA 2002, 99:949-954.
65. Vargas D.L., Nascimbene C., Krishnan C., Zimmerman A.W., Pardo C.A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005, 57:67-81.
66. Wortmann M., Peters A.S., Hakimi M., Böckler D., Dihlmann S. Glyoxalase I (Glo1) and its metabolites in vascular disease. Biochem Soc Trans 2014, 42:528-533.
67. Wu Y.Y., Chien W.H., Huang Y.S., Gau S.S., Chen C.H. Lack of evidence to support the glyoxalase 1 gene (GLO1) as a risk gene of autism in Han Chinese patients from Taiwan. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1740-1744.
68. Yasuda H., Kobayashi M., Yasuda Y., Tsutsui T. Estimation of autistic children by metallomics analysis. Sci Rep 2013, 3:1199.
69. Zilbovicius M., Meresse I., Chabane N., Brunelle F., Samson Y., Boddaert N. Autism, the superior temporal sulcus and social perception. Trends Neurosci 2006, 29:359-366.